All adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in all adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ All adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Adverse events: bone pain (all routes of bisphosphonate administration) · adults with cystic fibrosis who have not had a lung transplant
1 finding from 1 review
Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD
Cipaglucosidase plus miglustat showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa plus placebo (low certainty).
1 finding from 1 review
Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD
Avalglucosidase alfa showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa (low certainty).
1 finding from 1 review